-
Je něco špatně v tomto záznamu ?
Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey
J. Bronsky, L. de Ridder, FM. Ruemmele, A. Griffiths, S. Buderus, O. Hradsky, AC. Hauer,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- biosimilární léčivé přípravky terapeutické užití MeSH
- chirurgie trávicího traktu metody normy statistika a číselné údaje MeSH
- Crohnova nemoc diagnóza terapie MeSH
- dítě MeSH
- dodržování směrnic statistika a číselné údaje MeSH
- gastroenterologie metody normy statistika a číselné údaje MeSH
- gastrointestinální látky terapeutické užití MeSH
- idiopatické střevní záněty diagnóza terapie MeSH
- imunologické faktory terapeutické užití MeSH
- infliximab terapeutické užití MeSH
- lékařská praxe - způsoby provádění statistika a číselné údaje MeSH
- lidé MeSH
- mladiství MeSH
- pediatrie metody normy statistika a číselné údaje MeSH
- průzkumy zdravotní péče MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- ulcerózní kolitida diagnóza terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Kanada MeSH
- Německo MeSH
OBJECTIVES: Despite existence of international guidelines for diagnosis and management of inflammatory bowel diseases (IBD) in children, there might be differences in the clinical approach. METHODS: A survey on clinical practice in paediatric IBD was performed among members of the ESPGHAN Porto IBD working group and interest group, PIBD-NET, and IBD networks in Canada and German-speaking countries (CIDsCANN, GPGE), using a web-based questionnaire. Responses to 63 questions from 106 paediatric IBD centres were collected. RESULTS: Eighty-four percentage of centres reported to fulfil the revised Porto criteria in the majority of patients. In luminal Crohn disease (CD), exclusive enteral nutrition is used as a first-line induction therapy and immunomodulators (IMM) are used since diagnosis in the majority of patients. Infliximab (IFX) is mostly considered as first-line biological. Sixty percentage of centres have experience with vedolizumab and/or ustekinumab and 40% use biosimilars. In the majority of ulcerative colitis (UC) patients 5-aminosalicylates are continued as concomitant therapy to IMM (usually azathioprine [AZA]/6-MP). After ileocaecal resection (ICR) in CD patients without postoperative residual disease, AZA monotherapy is the preferred treatment. CONCLUSIONS: A majority of centres follows both the Porto diagnostic criteria as well as paediatric (ESPGHAN/ECCO) guidelines on medical and surgical IBD management. This reflects the value of international societal guidelines. However, potentially desirable answers might have been given instead of what is true daily practice, and the most highly motivated people might have answered, leading to some bias.
Department of Paediatrics Hospital for Sick Children University of Toronto Toronto Ontario Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025881
- 003
- CZ-PrNML
- 005
- 20201222155521.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MPG.0000000000002233 $2 doi
- 035 __
- $a (PubMed)30664566
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bronsky, Jiri $u Department of Paediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
- 245 10
- $a Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey / $c J. Bronsky, L. de Ridder, FM. Ruemmele, A. Griffiths, S. Buderus, O. Hradsky, AC. Hauer,
- 520 9_
- $a OBJECTIVES: Despite existence of international guidelines for diagnosis and management of inflammatory bowel diseases (IBD) in children, there might be differences in the clinical approach. METHODS: A survey on clinical practice in paediatric IBD was performed among members of the ESPGHAN Porto IBD working group and interest group, PIBD-NET, and IBD networks in Canada and German-speaking countries (CIDsCANN, GPGE), using a web-based questionnaire. Responses to 63 questions from 106 paediatric IBD centres were collected. RESULTS: Eighty-four percentage of centres reported to fulfil the revised Porto criteria in the majority of patients. In luminal Crohn disease (CD), exclusive enteral nutrition is used as a first-line induction therapy and immunomodulators (IMM) are used since diagnosis in the majority of patients. Infliximab (IFX) is mostly considered as first-line biological. Sixty percentage of centres have experience with vedolizumab and/or ustekinumab and 40% use biosimilars. In the majority of ulcerative colitis (UC) patients 5-aminosalicylates are continued as concomitant therapy to IMM (usually azathioprine [AZA]/6-MP). After ileocaecal resection (ICR) in CD patients without postoperative residual disease, AZA monotherapy is the preferred treatment. CONCLUSIONS: A majority of centres follows both the Porto diagnostic criteria as well as paediatric (ESPGHAN/ECCO) guidelines on medical and surgical IBD management. This reflects the value of international societal guidelines. However, potentially desirable answers might have been given instead of what is true daily practice, and the most highly motivated people might have answered, leading to some bias.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a biosimilární léčivé přípravky $x terapeutické užití $7 D059451
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ulcerózní kolitida $x diagnóza $x terapie $7 D003093
- 650 _2
- $a Crohnova nemoc $x diagnóza $x terapie $7 D003424
- 650 _2
- $a chirurgie trávicího traktu $x metody $x normy $x statistika a číselné údaje $7 D013505
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gastroenterologie $x metody $x normy $x statistika a číselné údaje $7 D005762
- 650 _2
- $a gastrointestinální látky $x terapeutické užití $7 D005765
- 650 _2
- $a dodržování směrnic $x statistika a číselné údaje $7 D019983
- 650 _2
- $a průzkumy zdravotní péče $7 D019538
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a idiopatické střevní záněty $x diagnóza $x terapie $7 D015212
- 650 _2
- $a infliximab $x terapeutické užití $7 D000069285
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a pediatrie $x metody $x normy $x statistika a číselné údaje $7 D010372
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a lékařská praxe - způsoby provádění $x statistika a číselné údaje $7 D010818
- 651 _2
- $a Kanada $7 D002170
- 651 _2
- $a Německo $7 D005858
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de Ridder, Lissy $u Department of Paediatric Gastroenterology, The Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Ruemmele, Frank M $u Department of Paediatric Gastroenterology, Université Paris Descartes, Sorbonne Paris Cité, APHP, Hôpital Necker Enfants Malades, Paris, France.
- 700 1_
- $a Griffiths, Anne $u Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- 700 1_
- $a Buderus, Stephan $u Department of Paediatrics, St. Marien Hospital, Bonn, Germany.
- 700 1_
- $a Hradsky, Ondrej $u Department of Paediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Hauer, Almuthe Christina $u GPGE-Educational Center for Paediatric Gastroenterology, Department of Paediatrics, Medical University of Graz, Graz, Austria.
- 773 0_
- $w MED00010080 $t Journal of pediatric gastroenterology and nutrition $x 1536-4801 $g Roč. 68, č. 5 (2019), s. 676-683
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30664566 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155516 $b ABA008
- 999 __
- $a ok $b bmc $g 1600026 $s 1116567
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c 5 $d 676-683 $e - $i 1536-4801 $m Journal of pediatric gastroenterology and nutrition $n J Pediatr Gastroenterol Nutr $x MED00010080
- LZP __
- $a Pubmed-20201125